IP Library Granted Patent US 7,998,195
Granted Patent B2
US 7,998,195 · App. 11/389,712 · Granted Aug 16, 2011

Device with engineered surface architecture coating for controlled drug release

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,998,195
App. No.
11/389,712
Granted
Aug 16, 2011
Kind
B2
Abstract

In one embodiment of the present invention a coating topology, or engineered surface architecture that may be referred to as a microdroplet deposited engineered surface architecture is provided. A plurality of drops are placed on the stent with the purpose, of building up individual units of coating material on the outer stent surface. This architecture results in a coating that uses less material, i.e., polymer, solvent, medicine, while at the same time providing for better, and determinable, drug kinetics, approaching 100% delivery and better mechanical operation of the coating binding to the stent.

Claims (50)

1. A stent comprising:

an abluminal surface; and

a plurality of discrete islands of first material deposited on the abluminal surface,

wherein each of the islands of first material has an outer surface and each of the islands comprises:

an inner section of first material having an inner height L 1 extending outwardly from the abluminal surface; and

an outer section of first material disposed about the inner section and having an outer height L 2 extending outwardly from the abluminal surface,

wherein the outer surface of each island is defined at least by the inner height of the inner section and the outer height of the outer section,

wherein the first material comprises a first polymer and a first drug,

wherein the outer height L 2 is greater than the inner height L 1 , and

wherein the first drug is released from the outer section of first material at a first rate of release, and the first drug is released from the inner section of first material at a second rate of release, wherein the second rate is greater than the first rate.

2. The stent of claim 1 , wherein the outer section of first material comprises:

an upper portion;

an intermediate portion; and

a lower portion,

wherein the upper portion is furthest away from the abluminal surface, the lower portion is closest to the abluminal surface, and intermediate portion is between the upper portion portion and the lower portion, and

wherein the first drug is released at a faster rate from the upper portion than the first drug is released from the intermediate portion, and the first drug is released from the intermediate portion at a faster rate than the first drug is released from the lower portion.

3. The stent of claim 1 , wherein the plurality of discrete islands comprises an index island relative to which each of the other islands of the plurality of islands is positioned.

4. The stent of claim 1 , wherein adjacent islands are separated from one another by a portion of the abluminal surface that is substantially free of deposited first material.

5. The stent of claim 1 , further comprising:

a plurality of discrete islands of second material deposited on the abluminal surface,

wherein the second material comprises a second polymer and a second drug,

wherein the second material is different than the first material, and

wherein each of the islands of second material comprises:

an inner section of second material having an inner height IL 1 extending outwardly from the abluminal surface; and

an outer section of second material disposed about the inner section and having an outer height IL 2 extending outwardly from the abluminal surface, and

wherein the outer height IL 2 is greater than the inner height IL 1 .

6. The stent of claim 5 , wherein adjacent islands of first and second material are separated from one another by a portion of the abluminal surface that is substantially free of deposited first or second material.

7. The stent of claim 5 , wherein, for a first island of first material and an adjacent island of second material:

the first island of first material comprises the first polymer and the first drug at a first ratio, by weight, to one another; and

the second island of second material comprises the second polymer and the second drug at a second ratio, by weight, to one another,

wherein the first drug is not the same as the second drug.

8. The stent of claim 1 , wherein:

the inner section comprises a second material.

9. The stent of claim 8 , wherein:

the first material comprises the first polymer and the first drug at a first ratio, by weight, to one another; and

the second material comprises a second polymer and a second drug at a second ratio, by weight, to one another, wherein the first drug is different from the second drug.

10. The stent of claim 1 , wherein:

at least one island of the plurality of islands of first material is disposed on another island of the plurality of islands.

11. The stent of claim 1 , wherein at least a portion of the abluminal surface comprises a therapeutic amount of a first medicinal compound deposited thereon.

12. The stent of claim 1 , wherein:

no island of the plurality of islands of first material is disposed on another island of the plurality of islands of first material.

13. The stent of claim 1 , wherein a first ratio of first polymer to first drug is in a range of 1:1 to 2:1 by weight.

14. The stent of claim 1 , wherein:

the inner section is a first elliptical portion; and

the outer section is a second elliptical portion.

15. The stent of claim 1 , wherein:

the inner section is a ring having a first radius R 1 ; and

the outer section is a ring having an inner radius substantially equal to the first radius R 1 and an outer radius R 2 ,

wherein the second radius R 2 is greater than the first radius R 1 .

16. The stent of claim 1 , wherein the first material comprises the first polymer and the first drug at a first ratio, by weight, to one another and wherein the first ratio is constant.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2010
From: LABCOAT LIMITED
To: BOSTON SCIENTIFIC LIMITED
Reel/Frame 024369/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2010
From: BOSTON SCIENTIFIC LIMITED
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 024369/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2006
From: ROSENTHAL, ARTHUR
To: LABCOAT, LTD.
Reel/Frame 017621/0340 →